126 related articles for article (PubMed ID: 24672081)
1. Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower-limb critical ischemia: An open-label, nonrandomized study in two cohorts.
Veroux P; Veroux M; Macarone M; Bonanno MG; Tumminelli MG
Curr Ther Res Clin Exp; 2004 May; 65(3):255-65. PubMed ID: 24672081
[TBL] [Abstract][Full Text] [Related]
2. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV).
Meini S; De Franco V; Auteri A; Setacci C; Di Renzo M; Pieragalli D
Int Angiol; 2005 Mar; 24(1):64-9. PubMed ID: 15877001
[TBL] [Abstract][Full Text] [Related]
4. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
[TBL] [Abstract][Full Text] [Related]
5. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
[TBL] [Abstract][Full Text] [Related]
6. [The role of iloprost in the treatment of critical ischemia of the limbs].
Poggesi L; Comeglio M
Ann Ital Med Int; 1993 Oct; 8 Suppl():71S-77S. PubMed ID: 7509614
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
8. [A new infusion method for a prostacyclin analogue].
Pibiri L; Petruzzo P; Angius D; Ruiu G; Polo F; Rescigno A; Brotzu G
Minerva Cardioangiol; 1997 Dec; 45(12):621-5. PubMed ID: 9577128
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients.
Staben P; Albring M
Prostaglandins Leukot Essent Fatty Acids; 1996 May; 54(5):327-33. PubMed ID: 8832761
[TBL] [Abstract][Full Text] [Related]
10. Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis.
Bixio R; Adami G; Bertoldo E; Giollo A; Morciano A; Bertelle D; Orsolini G; Idolazzi L; Rossini M; Viapiana O
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221137125. PubMed ID: 36439640
[TBL] [Abstract][Full Text] [Related]
11. [Prostacyclin (iloprost) as an adjuvant in local surgical therapy of stage IV arterial occlusive disease--is quantification of the therapeutic effect possible with tcPO2 measurements?].
Breuer C; Abri O
Vasa; 1995; 24(1):62-71. PubMed ID: 7536999
[TBL] [Abstract][Full Text] [Related]
12. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group.
Beischer W; Dembski JC; Gruss JD; Hofgärtner F; Horsch A; Horsch S; Kuhlmann HW; Loose DA; Mietaschk A; Schwilden ED; Spengel F; Spitzer W; Staben P; Stallkamp B; Stürzebecher CS; Tokhi M; von Bilderling P
Vasa; 1998 Feb; 27(1):15-9. PubMed ID: 9540427
[TBL] [Abstract][Full Text] [Related]
13. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease.
Blardi P; de Lalla A; Pieragalli D; De Franco V; Meini S; Ceccatelli L; Auteri A
Prostaglandins Other Lipid Mediat; 2006 Sep; 80(3-4):175-82. PubMed ID: 16939882
[TBL] [Abstract][Full Text] [Related]
14. Six years' experience with prostaglandin I2 infusion in elective open repair of abdominal aortic aneurysm: a parallel group observational study in a tertiary referral vascular center.
Beirne C; Hynes N; Sultan S
Ann Vasc Surg; 2008 Nov; 22(6):750-5. PubMed ID: 18992665
[TBL] [Abstract][Full Text] [Related]
15. Effect of Iloprost infusion on metabolism in critical limb ischemia, utilizing microdialysis. A pilot study.
Danielsson P; Metzsch C; Norgren L
Int Angiol; 2004 Sep; 23(3):259-62. PubMed ID: 15765041
[TBL] [Abstract][Full Text] [Related]
16. Plasma prothrombotic markers after a short- and middle term treatment with iloprost in arteriopathic patients with critical limb ischemia.
Ferlito S; Di Salvo MM; Attanasio L; Finocchiaro PM; Condorelli PM; Mazzone D
Panminerva Med; 1994 Jun; 36(2):76-9. PubMed ID: 7530356
[TBL] [Abstract][Full Text] [Related]
17. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost.
Balzer K; Bechara G; Bisler H; Clevert HD; Diehm C; Heisig G; Held K; Mahfoud Y; Mörl H; Rücker G
Int Angiol; 1991; 10(4):229-32. PubMed ID: 1724669
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study.
Int Angiol; 1994 Mar; 13(1):70-4. PubMed ID: 7521384
[TBL] [Abstract][Full Text] [Related]
19. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.
Hildebrand M
Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
